AMB – Quarterly Progress Report (Cumulative)

Year   
Normalized   

Quarterly Progress Report (QPR) on age-group wise service deliveries and information on distribution of Iron and Folic Acid (IFA) syrup and tablets- Pink, Blue & Red, Albendazole tablets among the 6 focused age groups. The information is derived on the basis of data updates available from HMIS indicators (Numerator) calculated using the eligible age specific respective denominators for each age group. *The GOI quarter reporting year starts from April and ends in March of the subsequent year (Q1-April to June, Q2-July to September, Q3- October to December and Q4 January to March (of subsequent year)).

Service Delivery in Percentage

India

Children 6-59 months


Year Upto       Q1 Upto       Q2 Upto       Q3 Upto       Q4
2021-2213.80.00.00.0
HMIS 9.9:
Percentage of children 6-59 months provided 8-10 doses (1ml) of Iron and Folic Acid (IFA) syrup (Bi weekly)
2020-2111.712.713.514.1
HMIS 9.9:
Percentage of children 6-59 months provided 8-10 doses (1ml) of Iron and Folic Acid (IFA) syrup (Bi weekly)
2019-2011.112.614.014.9
HMIS 9.9:
Percentage of children 6-59 months provided 8-10 doses (1ml) of Iron and Folic Acid (IFA) syrup (Bi weekly)
2018-197.47.78.08.3
HMIS 9.9:
Percentage of children 6-59 months provided 8-10 doses (1ml) of Iron and Folic Acid (IFA) syrup (Bi weekly)
2017-185.55.96.26.6
2021-221.90.00.00.0
HMIS 9.1:
Percentage of children 12-59 months provided Albendazole
2020-210.42.73.13.6
HMIS 9.1:
Percentage of children 12-59 months provided Albendazole
2019-200.73.12.52.9
HMIS 9.1:
Percentage of children 12-59 months provided Albendazole
2018-191.12.41.82.3
HMIS 9.1:
Percentage of children 12-59 months provided Albendazole
2017-180.52.01.52.1
Children 5-9 years


Year Upto       Q1 Upto       Q2 Upto       Q3 Upto       Q4
2021-2210.60.00.00.0
HMIS 23.1+23.3:
Percentage of children covered under WIFS JUNIOR (5-9 years) provided 4-5 iron and folic acid (IFA) tablets (In schools + out of school)
2020-2111.013.715.516.2
HMIS 23.1+23.3:
Percentage of children covered under WIFS JUNIOR (5-9 years) provided 4-5 iron and folic acid (IFA) tablets (In schools + out of school)
2019-2024.527.729.930.1
HMIS 23.1+23.3:
Percentage of children covered under WIFS JUNIOR (5-9 years) provided 4-5 iron and folic acid (IFA) tablets (In schools + out of school)
2018-1911.612.714.014.9
HMIS 23.1+23.3:
Percentage of children covered under WIFS JUNIOR (5-9 years) provided 4-5 iron and folic acid (IFA) tablets (In schools + out of school)
2017-188.69.29.18.8
2021-221.10.00.00.0
HMIS 23.2+23.4:
Percentage of children (5-9 years) provided albendazole (In schools + out of school)
2020-210.52.62.42.7
HMIS 23.2+23.4:
Percentage of children (5-9 years) provided albendazole (In schools + out of school)
2019-201.55.34.44.8
HMIS 23.2+23.4:
Percentage of children (5-9 years) provided albendazole (In schools + out of school)
2018-191.93.72.93.7
HMIS 23.2+23.4:
Percentage of children (5-9 years) provided albendazole (In schools + out of school)
2017-181.02.82.12.4
Adolescents 10-19 years


Year Upto       Q1 Upto       Q2 Upto       Q3 Upto       Q4
2021-2222.70.00.00.0
HMIS 22.1.1:
Percentage of (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools
2020-2112.616.619.020.9
HMIS 22.1.1:
Percentage of (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools
2019-2035.541.942.740.6
HMIS 22.1.1:
Percentage of (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools
2018-1926.727.828.328.0
HMIS 22.1.1:
Percentage of (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools
2017-1819.422.622.622.1
2021-2212.50.00.00.0
HMIS 22.1.3:
Percentage of out of school adolescent girls 10-19 years provided 4 Iron and Folic Acid (IFA) tablets at Anganwadi Centres
2020-2118.021.823.723.7
HMIS 22.1.3:
Percentage of out of school adolescent girls 10-19 years provided 4 Iron and Folic Acid (IFA) tablets at Anganwadi Centres
2019-2021.322.023.222.6
HMIS 22.1.3:
Percentage of out of school adolescent girls 10-19 years provided 4 Iron and Folic Acid (IFA) tablets at Anganwadi Centres
2018-1912.612.312.012.1
HMIS 22.1.3:
Percentage of out of school adolescent girls 10-19 years provided 4 Iron and Folic Acid (IFA) tablets at Anganwadi Centres
2017-187.17.67.47.1
2021-221.20.00.00.0
HMIS 22.1.2:
Percentage of (6-12 class) provided Albendazole in schools
2020-211.64.54.54.5
HMIS 22.1.2:
Percentage of (6-12 class) provided Albendazole in schools
2019-203.27.96.87.1
HMIS 22.1.2:
Percentage of (6-12 class) provided Albendazole in schools
2018-192.25.74.75.6
HMIS 22.1.2:
Percentage of (6-12 class) provided Albendazole in schools
2017-182.25.34.24.9
2021-223.90.00.00.0
HMIS 22.1.4:
Percentage of out of school adolescent girls 10-19 years provided Albendazole at Anganwadi Centres
2020-211.76.56.66.7
HMIS 22.1.4:
Percentage of out of school adolescent girls 10-19 years provided Albendazole at Anganwadi Centres
2019-202.65.04.13.9
HMIS 22.1.4:
Percentage of out of school adolescent girls 10-19 years provided Albendazole at Anganwadi Centres
2018-191.63.42.72.8
HMIS 22.1.4:
Percentage of out of school adolescent girls 10-19 years provided Albendazole at Anganwadi Centres
2017-181.12.01.61.8
2021-2222.80.00.00.0
HMIS 22.1.1.a:
Percentage of girls (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools
2020-2112.816.719.321.3
HMIS 22.1.1.a:
Percentage of girls (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools
2019-2035.839.541.439.6
HMIS 22.1.1.a:
Percentage of girls (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools
2018-1927.028.929.429.1
HMIS 22.1.1.a:
Percentage of girls (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools
2017-1819.823.123.322.7
2021-2222.50.00.00.0
HMIS 22.1.1.b:
Percentage of boys (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools
2020-2112.316.418.720.4
HMIS 22.1.1.b:
Percentage of boys (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools
2019-2035.144.444.241.5
HMIS 22.1.1.b:
Percentage of boys (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools
2018-1926.126.426.926.6
HMIS 22.1.1.b:
Percentage of boys (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools
2017-1819.022.022.021.4
2021-221.30.00.00.0
HMIS 22.1.2.a:
Percentage of girls (6-12 class) provided Albendazole in schools
2020-211.74.54.64.6
HMIS 22.1.2.a:
Percentage of girls (6-12 class) provided Albendazole in schools
2019-203.37.76.87.2
HMIS 22.1.2.a:
Percentage of girls (6-12 class) provided Albendazole in schools
2018-192.56.15.06.0
HMIS 22.1.2.a:
Percentage of girls (6-12 class) provided Albendazole in schools
2017-182.35.54.35.1
2021-221.10.00.00.0
HMIS 22.1.2.b:
Percentage of boys (6-12 class) provided Albendazole in schools
2020-211.64.54.44.5
HMIS 22.1.2.b:
Percentage of boys (6-12 class) provided Albendazole in schools
2019-203.18.06.87.0
HMIS 22.1.2.b:
Percentage of boys (6-12 class) provided Albendazole in schools
2018-191.95.34.45.1
HMIS 22.1.2.b:
Percentage of boys (6-12 class) provided Albendazole in schools
2017-182.15.14.14.7
Pregnant Women


Year Upto       Q1 Upto       Q2 Upto       Q3 Upto       Q4
2021-2290.20.00.00.0
2021-2276.90.00.00.0
HMIS 1.2.4:
Percentage of pregnant women (PW) given 180 Iron and Folic Acid (IFA) tablets (Registered Pregnancy)
2020-2186.590.592.992.6
HMIS 1.2.4:
Percentage of pregnant women (PW) given 180 Iron and Folic Acid (IFA) tablets (Registered Pregnancy)
2019-2087.589.390.390.8
HMIS 1.2.4:
Percentage of pregnant women (PW) given 180 Iron and Folic Acid (IFA) tablets (Registered Pregnancy)
2018-1980.382.183.784.8
HMIS 1.2.4:
Percentage of pregnant women (PW) given 180 Iron and Folic Acid (IFA) tablets (Registered Pregnancy)
2017-1870.773.576.177.3
2021-2250.70.00.00.0
2021-2243.30.00.00.0
HMIS 1.2.6:
Percentage of pregnant women (PW) given one Albendazole tablet after 1st trimester
2020-2147.148.349.149.0
HMIS 1.2.6:
Percentage of pregnant women (PW) given one Albendazole tablet after 1st trimester
2019-2040.642.143.043.7
HMIS 1.2.6:
Percentage of pregnant women (PW) given one Albendazole tablet after 1st trimester
2018-1935.236.037.137.5
HMIS 1.2.6:
Percentage of pregnant women (PW) given one Albendazole tablet after 1st trimester
2017-1824.826.928.329.3
2021-2262.80.00.00.0
HMIS 1.4.2:
Percentage of pregnant women (PW) having Hb level<11 (tested cases)(7.1 to 10.9)
2020-2161.663.364.664.8
HMIS 1.4.2:
Percentage of pregnant women (PW) having Hb level<11 (tested cases)(7.1 to 10.9)
2019-2068.770.871.471.1
HMIS 1.4.2:
Percentage of pregnant women (PW) having Hb level<11 (tested cases)(7.1 to 10.9)
2018-1970.970.671.470.8
HMIS 1.4.2:
Percentage of pregnant women (PW) having Hb level<11 (tested cases)(7.1 to 10.9)
2017-1862.965.466.766.4
2021-223.00.00.00.0
HMIS 1.4.3:
Percentage of pregnant women (PW) having Hb level<7 (tested cases)
2020-213.03.13.23.2
HMIS 1.4.3:
Percentage of pregnant women (PW) having Hb level<7 (tested cases)
2019-203.53.73.73.7
HMIS 1.4.3:
Percentage of pregnant women (PW) having Hb level<7 (tested cases)
2018-193.43.63.73.7
HMIS 1.4.3:
Percentage of pregnant women (PW) having Hb level<7 (tested cases)
2017-183.23.53.63.6
2021-221.70.00.00.0
HMIS 1.4.4:
Percentage of pregnant women (PW) having severe anemia (Hb<7) treated
2020-211.81.91.91.9
HMIS 1.4.4:
Percentage of pregnant women (PW) having severe anemia (Hb<7) treated
2019-202.22.32.32.2
HMIS 1.4.4:
Percentage of pregnant women (PW) having severe anemia (Hb<7) treated
2018-191.81.92.02.0
HMIS 1.4.4:
Percentage of pregnant women (PW) having severe anemia (Hb<7) treated
2017-181.41.61.71.6
Lactating Women 0-6 months


Year Upto       Q1 Upto       Q2 Upto       Q3 Upto       Q4
2021-220.00.00.00.0
HMIS 6.3:
Number of mothers provided full course of 180 Iron and Folic Acid (IFA) tablets after delivery
2020-2141.947.951.551.8
2020-2141.947.951.551.8
HMIS 6.3:
Number of mothers provided full course of 180 Iron and Folic Acid (IFA) tablets after delivery
2019-2041.946.649.149.8
2019-2041.946.649.149.8
HMIS 6.3:
Number of mothers provided full course of 180 Iron and Folic Acid (IFA) tablets after delivery
2018-1935.439.040.941.6
2018-1935.439.040.941.6
HMIS 6.3:
Number of mothers provided full course of 180 Iron and Folic Acid (IFA) tablets after delivery
2017-1826.931.433.934.6
2017-1826.931.433.934.6

Stock Availability

Stocks Available


Year Upto       Q1 Upto       Q2 Upto       Q3 Upto       Q4
2021-2253.80.00.00.0
HMIS 19.9:
Percentage of stocks available for Iron and Folic Acid (IFA) - Syrup (Paediatric)
2020-2146.948.146.143.7
HMIS 19.9:
Percentage of stocks available for Iron and Folic Acid (IFA) - Syrup (Paediatric)
2019-2053.650.952.152.4
HMIS 19.9:
Percentage of stocks available for Iron and Folic Acid (IFA) - Syrup (Paediatric)
2018-1933.942.545.746.7
HMIS 19.9:
Percentage of stocks available for Iron and Folic Acid (IFA) - Syrup (Paediatric)
2017-1831.928.130.335.0
2021-2226.10.00.00.0
2021-2226.10.00.00.0
HMIS 19.6:
Number of stocks available for Iron and Folic Acid (IFA) tablets - Red (Adult)
2020-2122.924.527.028.5
2020-2122.924.527.028.5
HMIS 19.6:
Number of stocks available for Iron and Folic Acid (IFA) tablets - Red (Adult)
2019-2032.033.633.230.7
2019-2032.033.633.230.7
HMIS 19.6:
Number of stocks available for Iron and Folic Acid (IFA) tablets - Red (Adult)
2018-1928.326.827.727.1
2018-1928.326.827.727.1
HMIS 19.6:
Number of stocks available for Iron and Folic Acid (IFA) tablets - Red (Adult)
2017-1815.121.422.423.3
2017-1815.121.422.423.3
2021-2239.90.00.00.0
HMIS 19.7:
Percentage of stocks available for Iron and Folic Acid (IFA) tablets - Blue (Adolescent 10-19 years)
2020-2142.546.846.845.0
HMIS 19.7:
Percentage of stocks available for Iron and Folic Acid (IFA) tablets - Blue (Adolescent 10-19 years)
2019-2049.953.553.451.3
HMIS 19.7:
Percentage of stocks available for Iron and Folic Acid (IFA) tablets - Blue (Adolescent 10-19 years)
2018-1954.051.148.345.0
HMIS 19.7:
Percentage of stocks available for Iron and Folic Acid (IFA) tablets - Blue (Adolescent 10-19 years)
2017-1841.835.633.035.7
2021-2238.70.00.00.0
HMIS 19.8:
Percentage of stocks available for Iron and Folic Acid (IFA) tablets - Pink (Junior 6-10 years)
2020-2151.368.166.762.1
HMIS 19.8:
Percentage of stocks available for Iron and Folic Acid (IFA) tablets - Pink (Junior 6-10 years)
2019-2068.067.765.562.7
HMIS 19.8:
Percentage of stocks available for Iron and Folic Acid (IFA) tablets - Pink (Junior 6-10 years)
2018-1961.151.048.551.3
HMIS 19.8:
Percentage of stocks available for Iron and Folic Acid (IFA) tablets - Pink (Junior 6-10 years)
2017-1817.717.917.120.8
HMIS 19.15:
Number of stocks available for Albendazole tablets
2020-2148.763.375.677.7
HMIS 19.15:
Number of stocks available for Albendazole tablets
2019-2011.033.824.726.4
HMIS 19.15:
Number of stocks available for Albendazole tablets
2019-2095.095.084.174.7
HMIS 19.15:
Number of stocks available for Albendazole tablets
2018-1917.331.424.828.8
HMIS 19.15:
Number of stocks available for Albendazole tablets
2018-1981.981.077.678.5
HMIS 19.15:
Number of stocks available for Albendazole tablets
2017-186.021.017.525.4
HMIS 19.15:
Number of stocks available for Albendazole tablets
2017-1827.731.635.643.9
Reporting Status


Year Upto       Q1 Upto       Q2 Upto       Q3 Upto       Q4
HMIS A.1:
Percentage of facilities reporting in the quarter
2019-2095.095.095.095.0
HMIS A.1:
Percentage of facilities reporting in the quarter
2018-1995.095.095.095.0
HMIS A.1:
Percentage of facilities reporting in the quarter
2017-1895.095.095.095.0